10 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Localised penile cancer is squamous cell cancer confined to the penis with no spread to the groin lymph nodes, and the aim of treatment is to remove the tumour while keeping as much of the penis as possible. Precancer and small tumours are treated with creams, laser or glans-sparing surgery, and the groin nodes are checked by sentinel node biopsy or surveillance rather than removed wholesale.
Penile squamous cell carcinoma begins on the glans, the inner foreskin or the coronal sulcus, in roughly a third to a half of cases driven by HPV (basaloid and warty types, p16 positive) and otherwise by chronic inflammation, lichen sclerosus and phimosis (usual, verrucous and sarcomatoid types, often TP53 mutant). Penile intraepithelial neoplasia (PeIN) is its precursor. The 2023 EAU-ASCO guideline places organ preservation at the centre of care: PeIN and superficial tumours are treated with topical fluorouracil or imiquimod, laser ablation, circumcision or glans resurfacing; T1 and T2 tumours with glansectomy or partial penectomy with a margin of a few millimetres, which oncological series have shown to be safe; and brachytherapy is an alternative for small distal tumours. Total penectomy is kept for large or proximal tumours.
What decides survival is the groin. Palpably normal nodes still hide metastases in 20 to 25 percent of patients, so the guideline recommends surgical staging, by dynamic sentinel node biopsy where it is available, for high-risk tumours (T1 with lymphovascular or perineural invasion or poor differentiation, and any T2 or worse). For intermediate-risk tumours (moderately differentiated T1 without those features), where the chance of hidden spread is 6 to 8 percent, the guideline weighs staging against its morbidity case by case, and low-risk tumours are followed by surveillance; if the sentinel node is positive the patient moves into node-positive management. Circumcision and HPV vaccination prevent much of the disease, and the rarity of penile cancer is why the guideline recommends referral to a centre of expertise, the model England adopted after NICE's guidance on urological cancers of September 2002 (since retired; its text could not be re-read on 18 November 2026).
| Setting | Approach | Guideline |
|---|---|---|
| Penile intraepithelial neoplasia | Circumcision if the foreskin is involved; topical fluorouracil or imiquimod, laser ablation or glans resurfacing; close follow-up because recurrence is common. | not mapped |
| T1 to T2 tumours | Organ-sparing surgery (wide local excision, glansectomy, partial penectomy) with narrow margins; brachytherapy for small distal tumours; total penectomy only for large or proximal disease. | not mapped |
| Clinically negative groins | Surveillance for low-risk tumours (Ta, T1 grade 1 without lymphovascular or perineural invasion); dynamic sentinel node biopsy for high-risk tumours (T1 with lymphovascular or perineural invasion or poor differentiation, T2 or worse), decided case by case for intermediate-risk tumours (T1 grade 2 without those features), with inguinal lymphadenectomy if positive. | not mapped |
| Prevention | HPV vaccination (now offered to boys in many countries and being tested in Chinese men) and treatment of phimosis and lichen sclerosus. | not mapped |